Scinai Immunotherapeutics (SCNI) Total Non-Current Liabilities (2017 - 2026)

Scinai Immunotherapeutics (SCNI) has 10 years of Total Non-Current Liabilities data on file, last reported at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (changed N/A YoY), and the FY2025 full-year result was $1.9 million, up 16.4% from the prior year.
• Total Non-Current Liabilities rose to $3.1 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $26.5 million in Q4 2022 to a low of $866000.0 in Q3 2024.
• A 5-year average of $14.3 million and a median of $18.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 734.22% in 2022 and plunged 95.61% in 2024, its largest moves.
• Tracing SCNI's Total Non-Current Liabilities over 5 years: stood at $26.5 million in 2022, then retreated by 23.51% to $20.3 million in 2023, then tumbled by 91.78% to $1.7 million in 2024, then grew by 16.4% to $1.9 million in 2025, then jumped by 62.13% to $3.1 million in 2026.
• Business Quant data shows SCNI's Total Non-Current Liabilities at $3.1 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q2 2025.